NasdaqGM:CSTLHealthcare
How Investors May Respond To Castle Biosciences (CSTL) Raising 2025 Revenue Outlook On Strong Test Demand
Castle Biosciences recently reported preliminary, unaudited results for the fourth quarter and full year 2025, highlighting a jump in core test volumes for DecisionDx-Melanoma and TissueCypher, and now expects 2025 revenue to exceed US$340 million, above its prior guidance range.
An interesting angle for investors is how the rapid uptake of TissueCypher and the limited launch of AdvanceAD-Tx are broadening Castle’s test portfolio and expanding its addressable patient base across dermatology...